Why Is Autolus Therapeutics (NASDAQ:AUTL) Edging Up 8.33% Pre-Market Before Its Q3 Results?

Vinay Lochav

10 November 2026 11:43 PM AEDT

Why Is Autolus Therapeutics (NASDAQ:AUTL) Edging Up 8.33% Pre-Market Before Its Q3 Results?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Autolus Therapeutics (NASDAQ:AUTL) is indicated at USD 1.43 pre-market on Tuesday, November 10, 2026, 8.33% above a calculated prior close of USD 1.32 on Monday, November 9.
The company scheduled third quarter results ahead of the U.S. open on November 10, with a call at 8:30 a.m. ET; no reported figures had been confirmed at the time of writing.
In August 2026 the company raised its 2026 AUCATZYL net product Revenue guidance to USD 140 million to USD 150 million, from USD 120 million to USD 135 million.
At USD 1.43 and about 266.16 million shares, calculated Market Value is near USD 380.6 million, within a 52-week range of USD 1.175 to USD 2.58.

What Drove Autolus Therapeutics in Pre-Market Trade (8.33%)

The ADS is indicated at USD 1.43 before the open on Tuesday, November 10, 2026, a rise of USD 0.11 from a calculated prior close of USD 1.32. The likely trigger is positioning ahead of the quarterly report, which the company said it would release before U.S. markets open, with a conference call at 8:30 a.m. ET. No published coverage of the actual results had been located when this was written, so no Earnings figure is stated here. Earlier disclosures add context: preliminary second quarter AUCATZYL net product revenue was about USD 45 million, up roughly 70% from the first quarter and above 100% from the second quarter of 2025. First half gross Margin was about 35%, against about negative 20% in the second half of 2025.

How Commercial Cell Therapy Shares React on Results Days

As general background, a cell therapy company with one marketed product is valued on its sales ramp, gross margin and cash runway. Each quarter shows whether treatment centres are adding patients to AUCATZYL, an obecabtagene autoleucel therapy for adult B-cell acute lymphoblastic leukaemia. Guidance of USD 140 million to USD 150 million sets the bar, and a result at or above it can lift shares ahead of the print. Financing matters too: a senior Credit Facility of up to USD 250 million with Perceptive Advisors included USD 75 million issued on July 30, 2026, at one-month SOFR (3.50% floor) plus 7.25%. The company said cash runway extends into the second quarter of 2028. A Warrant covers up to 3.5 million ADSs at USD 1.9314.

Valuation, Trading Depth and Risks Around the Result

Published market data lists trailing revenue of USD 117.39 million, up 292.2%, against a net loss of USD 280.16 million, so the Business is not yet profitable. The consensus target is USD 8.73 from 9 analysts, averaging Strong Buy, a third-party view far above the USD 1.43 quote. Risks include a results miss, slower patient additions, interest costs on the facility, dilution if the warrant is exercised, wide pre-market spreads and a sharp Reversal after the call. The ADS trades 45% below the 52-week high of USD 2.58, calculated. An 8.33% gain before a report says nothing about the outcome, and a stock near USD 1.43 also sits close to the USD 1.00 Nasdaq minimum bid threshold.

Where Things Stand

Autolus Therapeutics (NASDAQ:AUTL) is up 8.33% pre-market on November 10, 2026, mainly because third quarter results and an 8:30 a.m. ET call land that morning, and traders are positioning ahead of them. No results figures were confirmed, so the USD 1.43 quote rests on expectations built from raised guidance of USD 140 million to USD 150 million and a runway into the second quarter of 2028.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.